Bio-Path announces completion of higher dose second cohort in trial of BP1002

Bio-Path Holdings announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients, including venetoclax-resistant patients. “We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration to review patient study data,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.”